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Method: A systematic literature review (using PRISMA guidelines)
identified factors associated with the development and severity of
AWS used to develop a 10-item scale to predict alcohol dependent
patients at risk for developing complicated AWS (i.e., seizures and
DT). We prospectively recruited all consecutively hospitalized
subjects to the general medicine units over a 3-mo period to test
PAWSS' validity and reliability. Subjects were independently and
blindly assessed daily with PAWSS, CIWA-Ar, and clinical monitoring
throughout their admission to determine the presence and severity
of AWS.
Results: 409 patients were tested and grouped by PAWSS score:
Group A included those with a PAWSS b 4 and were considered to be
at low risk for AWS; while subjects in Group B obtained a PAWSS N 4
andwere considered at high risk for complicated AWS. Two patients in
Group A experienced elevated CIWA scores or were treated for AWS.
As predicted, all but two subjects in Group B required pharmacological
treatment for AWS. The results of this study suggest that, using a
PAWSS cut-off of 4, the tool's sensitivity is 93.5%, specificity is 99.5%,
positive predictive value is 93.5%, and negative predictive value is
99.5%.
Conclusion: PAWSS appears to have excellent psychometric
characteristics and predictive value among medically-ill in-
patients, helping clinicians identify those at risk for complicated
AWS and allowing for timely prophylactic treatment. The use of
PAWSS will minimize the excessive use of medications in those at
low risk for complicated AWS, thus minimizing undesirable side
effects.
doi:10.1016/j.jpsychores.2015.03.091
Neuroimaging of the joint hypermobility syndrome: The role of
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Background: Joint hypermobility, an expression of a common
variation in the connective tissue protein collagen, is increasingly
recognized as a risk factor to anxiety, pain, fatigue and related
disorders (including anxiety disorders, fibromyalgia, irritable bowel
syndrome, temporomandibular joint disorder). However the neural
underpinnings of these associations still remain unclear. This study
explored brain responses to facial visual stimuli with emotional cues
using fMRI techniques in general population with different ranges of
hypermobility.
Method: The final sample consisted of fifty-one non-clinical volunteers
(thirty-threewomen) thatwere assessedwith a clinical examination for
hypermobility, completed state and trait anxiety questionnaire mea-
sures and performed an emotional face processing paradigm during
functional neuroimaging.
Results: Trait anxiety scores significantly correlated with state
anxiety and hypermobility scores. BOLD signals of the hippocampus
positively correlated with hypermobility scores for the crying faces
versus neutral faces contrast in ROI analyses. No results were found
for any of the other preselected regions of interest (ROIs, previously
described as important affective processing regions). However,
hypermobility scores were associated with key affective processing
areas (i.e. the middle and anterior cingulate gyrus, fusiform gyrus,
parahippocampal region, orbitofrontal cortex and cerebellum) in the
whole brain analysis.
Conclusion: Hypermobility scores are associated with trait anxiety
and higher brain responses to emotional faces in emotion
processing brain areas (including hippocampus) described to be
linked to anxiety and somatic symptoms. These findings increase
our understanding of emotion processing in people bearing this
heritable variant of collagen and the mechanisms through which
vulnerability to anxiety and somatic symptoms arises in this
population.
doi:10.1016/j.jpsychores.2015.03.092
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Background: Mental disorders are highly prevalent in rheumatoid
arthritis (RA) and are associated with poorer physical health
outcomes in cross sectional studies. The aim of this analysis is to
examine the longitudinal impact of symptoms of depression/anxiety
on treatment response and long-term physical health in rheumatoid
arthritis.
Method: Secondary analysis of clinical trial data was performed. Data
were collected at baseline and at 6-monthly intervals for 2 years. The
EuroQol (EQ-5D) identified depression/anxiety symptom severity.
Our primary outcomes of interest were 1) disease activity (DAS-28)
and its components: tender and swollen joint counts, patient global
assessment and erythrocyte sedimentation rate (ESR); and 2) physical
disability measured via the Health Assessment Questionnaire (HAQ).
Secondary outcomes were assessor global assessment (AGA), Larsen
score, pain levels, and odds of reaching clinical remission. Multi-level
models assessed the impact of baseline and persistent depression/
anxiety on outcomes over 2-years.
Results: Data from 379 patients were included. After adjusting for
covariates, baseline depression/anxiety symptoms were associated with
increased tender joint counts (TJC) and DAS-28 outcomes. Persistent
depression/anxiety symptoms significantly predicted increased DAS-28,
HAQ, TJC, patient and assessor global assessment, pain, reduced Larsen
scores, and reduced odds of reaching clinical remission at 2-years.
Patients with symptoms of depression/anxiety at baseline had a reduced
treatment effect of prednisolone onHAQ by almost half, in comparison to
patients with no symptoms of depression/anxiety at baseline.
Conclusion: Baseline and persistent symptoms of depression/anxiety
predict several objectively- and subjectively-measured physical health
outcomes over time, as well as substantially reducing prednisolone
treatment response. We suggest that mental health should be routinely
measured both in clinical practice and in research, and managed
alongside rheumatological disease to optimise health outcomes. Further
research is required to examinewhether treatment of mental disorders
can improve rheumatological outcomes.
doi:10.1016/j.jpsychores.2015.03.093
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Background: Metabolic syndrome (MetS) is a heterogeneous entity
represented by the coexistence of multiple alterations: abdominal
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adiposity, impaired glucose tolerance, hypertriglyceridemia, HDL
hypocolesterolemia and hypertension. Symptoms of anxiety and
depression are frequently comorbid with MetS. Aim of the present
study was to measure the association between symptoms of anxiety
and depression with the five criteria of MetS in outpatients attending
GPs' practices.
Method: This is a cross-sectional study, involving male and female
patients aged 40–80 attending five GPs' practices within one month
in Modena, Northern Italy approved by the local Ethical Committee.
All patients were screened for the presence of MetS and depressive/
anxiety symptoms, using the Hospital Anxiety and Depression Scale.
Exclusion criteria: age b40 or N80; use of antidepressants or
antipsychotics; previous stroke, heart attack or cardiovascular
disease; diagnosed psychotic or mood disorder (according to the
DSM-IV-TR); diabetes; pregnancy; hereditary disease linked to
obesity. All data were adjusted for socio-demographic confounders.
Multiple logistic analysis performed with STATA 13.0.
Results: 128 subjects were enrolled in the study (55 men and 73
women), 48 presented with MetS (ATP-III-Revised criteria). MetS
was associated with depression only in the female group (OR = 6.33,
p = 0.01), also when adjusting for age (OR = 5.13, p = 0.02). MetS
was not associated with anxiety in both males and females, and with
depression in men. Among the individual components of MetS,
only waist circumference was associated with anxiety in the female
group (OR= 4.40, p = 0.04) also when adjusting for age (OR= 4.34,
p = 0.04).
Conclusion: Women aged between 40 and 60, presenting with MetS
and attending the primary care services should been regularly
screened for the presence of depression. Chronic systemic inflam-
mation could represent the biological link between MetS and
psychological symptoms. Further researches are needed to better
clarify this possible relation.
doi:10.1016/j.jpsychores.2015.03.094
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Background: The typical patient needing long term oral anti-
coagulation is elder and highly comorbid. Elevated symptoms of
depression and anxiety are highly prevalent in chronic medical
conditions. However, studies are sparse investigating the impact of
elevated depressive symptoms on patients undergoing term oral
anticoagulation (OAC). Therefore, we examined in outpatients with
long term oral anticoagulation (OAC) whether symptoms of
depression and anxiety are associated with all-cause mortality.
Method: For determining depression and anxiety we applied the
PHQ-2 and GAD-2 respectively. The sample comprised n = 1384
patients from a regular medical care setting receiving long-term OAC
with vitamin K antagonists. At baseline, symptoms of anxiety and
depression were assessed with the PHQ-2 and GAD-2. The past
medical history was also taken. The outcome was all-cause mortality
in the 24 months observation period.
Results: The mean follow-up period per patient was 15.8 months with
a standard deviation of 7.9 months. The death rate was 13.8%; 191
patients from n= 1384 died. Clinical significant depression as deter-
mined by PHQ-2≥ 2 was associated with a 51% increase in mortality
(hazard ratio [HR] 1.51, 95% confidence interval [95%CI] 1.12 2.04) after
adjustment for age, sex, high school graduation, partnership, smoking,
obesity, frailty according to the Barthel Index, Charlson Comorbidity
Index and CHA2DS2-VASc score. Anxiety as determined by GAD-2 ≥ 3
increased mortality by 65% respectively (HR 1.65, 95%CI 1.08–2.52) in
the fully adjusted regressionmodel. In contrast with current symptoms
of depression and anxiety a past medical history of any mental disorder
did not predict excess mortality.
Conclusion: The ultra short screening instruments, PHQ-2 and GAD-
2, provide valuable prognostic information. These results emphasize
the need for implementing regular screening procedures and the
development and evaluation of appropriate psychosocial treatment
approaches for OAC patients.
doi:10.1016/j.jpsychores.2015.03.152
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Aim: To investigate the relationship between daily physical activity
(PA) and cognitive performance in extreme obesity.
Method: Seventy-one participants (77.5% women) with a mean body
mass index (BMI) of 46.9 kg/m2 (SD 6.0) and a mean age of 41.4 (SD
11.9) years completed Sense Wear Pro2 activity monitoring for a
period of seven days. Neurocognitive functioning was assessed by a
computerized test battery, including tasks of executive function
(Iowa Gambling Task), visuospatial short-term memory (Corsi Block
Tapping Test) and verbal short-term memory (Auditory Word
Learning Task). Furthermore, questionnaires assessing eating distur-
bances and depressive symptoms were administered. Somatic
comorbidities were assessed by medical chart review.
Results: Physical activity level in the sample was low with mean steps
per day within wear time being 7140 (SD= 3422). The majority of
participants were categorized as sedentary (31.0%) or low active
(26.8%). After adjusting for multiple testing, no significant association
between PA estimates and cognitive performance was found. Lower PA
was modestly correlated with higher BMI but not with age, somatic
comorbidity or depressive symptoms. Group comparisons of patients
with (29.6%) and without (70.4%) regular binge eating did not reveal
significant differences in PA or cognitive function.
Conclusion: The findings indicate no association between daily PA
and neurocognitive performance in morbidly obese patients. Future
studies should explore the relationship between the variables with
regard to a broader BMI range and with respect to potential changes
after substantial weight loss due to bariatric surgery.
doi:10.1016/j.jpsychores.2015.03.097
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